Results 211 to 220 of about 2,653,643 (293)

Duck Orbivirus and Egg Production: A Newly Identified Duck Orbivirus Is the Etiological Agent of Egg Production Decline in Chinese Breeder Ducks

Animal Research and One Health, EarlyView.
Field samples from breeder duck farms with egg‐production decline were subjected to viral detection, genome sequencing, and virus isolation. Experimental infection demonstrated that duck orbivirus (DORV) causes a significant and persistent reduction in egg production in breeder ducks.
Bing Li, Jianhua Wang, Xuezhi Cui, Xinxing Chu, You Wang, Dongmin Hao, Mingqing Xu, Haixia Chang, Huihui Li, Mingtian Mao, Mian Wu, Chengguang Lu, Jing Tang, Suyun Liang, Zhanbao Guo, Zhengkui Zhou, Youxiang Diao, Shuisheng Hou, Yi Tang   +18 more
wiley   +1 more source

The HTRA1-Extracellular Matrix Axis in Health and Disease: From Pathological Remodeling to Therapeutic Opportunities in Fibrosis, Osteoarticular Disorders, and Cancer. [PDF]

Curr Issues Mol Biol
Zong L, Xiong L, Wang Y, Zhu M, Li J, Xu J, Li H, Yan L.   +7 more
europepmc   +1 more source

Use of Clotrimazole in Finfish Aquaculture: Mechanistic Insights, Limitations, and Future Directions for Antifungal Therapy

Animal Research and One Health, EarlyView.
This review critically evaluates clotrimazole as a potential antifungal for finfish aquaculture, highlighting strong mechanistic and in vitro efficacy against aquatic mycoses alongside major gaps in in vivo evidence, toxicokinetics, residue safety, and environmental risk, outlining priorities for responsible therapeutic development and regulatory ...
Arya Sen, Debashri Mondal, Thangapalam Jawahar Abraham   +2 more
wiley   +1 more source

Pararectal aggressive angiomyxoma with bilateral ovarian endometriomas cysts: a rare case report. [PDF]

Front Oncol
Ji N, Kong X, Huang J, Wang N.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Research progress on the role of IL‑37 in gynecological and obstetrics‑related diseases (Review). [PDF]

Int J Mol Med
Wang H, Arjune R, Gan W, Guo N, Yu N, Xiong T.   +5 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Incidence and factors associated with premature ovarian insufficiency: a population-based cohort study. [PDF]

Hum Reprod
Macintyre JN, Pudwell J, Shellenberger J, Velez MP.   +3 more
europepmc   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source